TICKERNERD
Menu
OCULOCULHealthcare · Biotechnology

OCUL Stock Forecast: Ocular Therapeutix, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$10
−0.59% on the day

The 11 Wall Street analysts covering Ocular Therapeutix, Inc. hold a median 12-month price target of $28 — +178.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.2B
Ticker Nerd rank
33 / 100
Median analyst target
$28
Analysts covering
11
Total return, dividends reinvested
1W
+9.2%
1M
+3.5%
YTD
−17.3%
1Y
−20.6%
From 52W high
−37.7%
From 52W low
+45.9%
$7
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OCUL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ocular Therapeutix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
76
Value
48
Accruals
45
Quality
43
Momentum
40
Volatility
39
Growth
38
Size
36
Issuance
24

Revisions (76): Analysts have, on balance, been raising their forecasts.

Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OCUL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OCUL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26OCULHigh $34Median $28Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $18Median $28High $34

The green dot is the last close — the median target sits +178.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Aug 2026Chardan CapitalMaintainsBuy$23
25 June 2026Chardan CapitalMaintainsBuy—
25 June 2026Chardan CapitalMaintainsBuy$21 → $23
18 June 2026BairdMaintainsOutperform—
18 June 2026BairdMaintainsOutperform$24 → $30
18 June 2026HC Wainwright & Co.ReiteratesBuy—
18 June 2026HC Wainwright & Co.ReiteratesBuy$21 → $25
6 May 2026RBC CapitalReiteratesOutperform—
5 May 2026NeedhamReiteratesBuy—
13 Apr 2026HC Wainwright & Co.ReiteratesBuy—
3 Mar 2026Clear StreetMaintainsBuy—
20 Feb 2026NeedhamMaintainsBuy—
18 Feb 2026Chardan CapitalMaintainsBuy—
9 Dec 2025Chardan CapitalMaintainsBuy—
8 Dec 2025HC Wainwright & Co.MaintainsBuy—
8 Dec 2025NeedhamReiteratesBuy—
25 Nov 2025HC Wainwright & Co.ReiteratesBuy—
5 Nov 2025Chardan CapitalMaintainsBuy—
30 Oct 2025TD CowenMaintainsBuy—
8 Oct 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OCUL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

OCUL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Ocular Therapeutix, Inc. (OCUL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.1×

Cheaper than 91% of US stocks

Price / sales
42.4×

Cheaper than 6% of US stocks

Price / book
4.2×

Cheaper than 26% of US stocks

EV / EBITDA
−5.5×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
0.1%

Higher than 28% of US stocks

Earnings growth (YoY)
0.1%

Higher than 36% of US stocks

Gross margin
85.1%

Higher than 94% of US stocks

Operating margin
−609.3%

Higher than 7% of US stocks

Net margin
87.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−73.0%

Higher than 17% of US stocks

Return on assets
−35.0%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OCUL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OCULOcular Therapeutix, Inc.$2.2B
33
BHVNBiohaven Ltd.$2.1B
24
ADMAADMA Biologics, Inc.$2.1B
42
NUVBNuvation Bio, Inc.$2.1B
62
PGENPrecigen, Inc.$2.2B
80
RAPPRapport Therapeutics, Inc.$2.2B
42
HRMYHarmony Biosciences Holdings, Inc.$2.2B
84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ocular Therapeutix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OCUL news & analysis

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 13 Aug 2026neutral

Ocular Therapeutix announced it granted inducement stock awards under its 2019 Inducement Stock Incentive Plan to Beth Rada, its new SVP of Government Affairs and Public Policy, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards serve as an inducement for her acceptance of employment with the company.

Why it matters — OCUL watchers would note the hiring of a new senior leadership member in government affairs and public policy, signaled by the inducement grant.

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 7 Aug 2026neutral

Ocular Therapeutix announced that it has granted inducement equity awards to eight newly hired non-executive employees, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants were made under the company's inducement award program.

Why it matters — This routine announcement signals the company's efforts to attract and retain new talent through equity compensation, which is relevant to shareholders tracking management incentives and hiring.

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Seeking Alpha · 5 Aug 2026positive

According to the article, Ocular Therapeutix is positioned for a potential 2027 launch of AXPAXLI, citing a de-risked regulatory path and strong Phase 3 efficacy data. The FDA has agreed to an NDA submission in Q4 2026 based on SOL-1 data and interim safety from SOL-R, and the drug's features could support expansion beyond wet AMD into broader retinal indications such as diabetic retinopathy.

Why it matters — The FDA's agreement on the Q4 2026 NDA submission path reduces near-term regulatory risk for AXPAXLI, which could broaden OCUL's commercial prospects across additional retinal indications.

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 3 Aug 2026positive

Ocular Therapeutix (OCUL) reported a second-quarter loss of $0.35 per share, better than the Zacks Consensus Estimate of a $0.40 loss and an improvement over the $0.39 per-share loss from a year ago. The company beat revenue estimates for the quarter.

Why it matters — OCUL watchers would care because the quarterly loss came in narrower than analyst expectations, indicating results were stronger than forecast.

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

GlobeNewsWire · 3 Aug 2026positive

Ocular Therapeutix reported its second quarter 2026 financial results and business highlights, noting that its AXPAXLI wet AMD NDA submission remains on track for the fourth quarter of 2026 following a positive Type C meeting with the U.S. FDA in May 2026.

Why it matters — An OCUL watcher would care because the company is reaffirming the timeline for its key wet AMD drug candidate's regulatory submission after a favorable FDA meeting, marking a significant pipeline milestone.

FAQ

Frequently asked questions about OCUL stock

What is the OCUL stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Ocular Therapeutix, Inc. have a median 12-month price target of $28, with estimates ranging from $18 to $34. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OCUL stock a buy right now?

Of the 11 analysts covering Ocular Therapeutix, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ocular Therapeutix, Inc. 33 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OCUL?

As at 15 Aug 2026, Ocular Therapeutix, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (76 of 100).

Will OCUL stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +178.9% from the last close, and Ticker Nerd's factor model ranks Ocular Therapeutix, Inc. 33 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OCUL stock forecast for 2030?

No analyst covering Ocular Therapeutix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCUL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $34 over the next 12 months.

How has OCUL stock performed over the past year?

Ocular Therapeutix, Inc. returned -20.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ocular Therapeutix, Inc. do?

Ocular Therapeutix Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye.

What is the latest news on OCUL?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Ocular Therapeutix announced it granted inducement stock awards under its 2019 Inducement Stock Incentive Plan to Beth Rada, its new SVP of Government Affairs and Public Policy, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards serve as an inducement for her acceptance of employment with the company.

Company

About Ocular Therapeutix, Inc.

Ocular Therapeutix Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. It specializes in ophthalmology, particularly advancing treatments for retinal disorders such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR). The company's pipeline features AXPAXLI (OTX-TKI), a tyrosine kinase inhibitor delivered via intravitreal bioresorbable implant designed for extended durability, currently in late-stage Phase 3 clinical programs including the SOL-1 superiority trial and HELIOS registrational program. Ocular Therapeutix Inc. also markets DEXTENZA, a commercial intracanalicular insert for ocular pain and inflammation post-surgery. Additional candidates like OTX-TP target glaucoma and dry eye disease. Headquartered in Bedford, Massachusetts and founded in 2006, the company plays a key role in the retinal therapeutics market by leveraging bioresorbable hydrogel technology to improve patient outcomes and reduce treatment burden through sustained drug delivery systems.

CEO Dr. Pravin U. Dugel M.D. · 325 employees · United States · https://www.ocutx.com